Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Allena Pharmaceuticals, Inc. (NASDAQ: ALNA).

Full DD Report for ALNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: ALNA)

Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
NEWTON, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...
Source: GlobeNewswire
Date: August, 07 2018 16:01
Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update
- Enrolling Global Phase 3 URIROX-1™ Trial; Plan to Initiate URIROX-2™ in 2H18 - - Treated First Patients in Phase 2 Basket Study of Reloxiliase (ALLN-177) for Primary Hyperoxaluria or Enteric Hyperoxaluria with Advanced Chronic Kidney Disease (CKD) - - Completed Ani...
Source: GlobeNewswire
Date: August, 07 2018 08:00
Allena Pharma's mid-stage basket study of ALLN-177 in hyperoxaluria underway
The first subjects have been treated in an open-label Phase 2 basket study (Study 206) evaluating Allena Pharmaceuticals' (NASDAQ: ALNA ) lead candidate ALLN-177 in adults and adolescents with primary hyperoxaluria or enteric hyperoxaluria with advanced kidney disease and elevated plasma...
Source: SeekingAlpha
Date: July, 23 2018 09:20
Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease
NEWTON, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...
Source: GlobeNewswire
Date: July, 23 2018 08:00
Your Daily Pharma Scoop: Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta Surges
Analysis Focus: ANIK Anika Therapeutics ( ANIK ) announced failure of its candidate CINGAL to achieve primary endpoint in a Phase 3 clinical trial in knee osteoarthritis (‘OA). CINGAL could not succeed in showing a statistically significant reduction in knee pain. CINGAL is a combin...
Source: SeekingAlpha
Date: June, 21 2018 08:00
Allena Pharma to file IND for ALLN-346 in H1 2019
Allena Pharmaceuticals ( ALNA -0.6% ) has completed an animal proof-of-concept study supporting the rationale for ALLN-346 for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients with associated chronic kidney disease (CKD). More news on: Allena Pharmaceutic...
Source: SeekingAlpha
Date: June, 19 2018 10:02
Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
-- ALLN-346, a Novel, Engineered, Urate Oxidase, Demonstrates Robust Reduction of Plasma and Urine Uric Acid After Oral Administration in an Animal Model of Hyperuricemia --  -- Data Supports Advancement of ALLN-346 as Allena’s Next Product Candidate for the Treatment of Meta...
Source: GlobeNewswire
Date: June, 19 2018 08:00
Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors
NEWTON, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, to...
Source: GlobeNewswire
Date: June, 11 2018 08:00
Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference
NEWTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disor...
Source: GlobeNewswire
Date: May, 30 2018 08:00
Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
-- Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria -- -- Reiterates Guidance for Key Objectives Across Portfolio-- NEWTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late...
Source: GlobeNewswire
Date: May, 08 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0810.4410.4010.7010.2434,984
2018-05-1716.1516.0016.6015.8644418,624

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-118329328.3276Cover
2018-12-101,7725,02535.2637Short
2018-12-072,3448,62627.1737Cover
2018-12-062,02610,01420.2317Cover
2018-12-042,8215,47951.4875Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ALNA.


About Allena Pharmaceuticals, Inc. (NASDAQ: ALNA)

Logo for Allena Pharmaceuticals, Inc. (NASDAQ: ALNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: ALNA)

      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 25 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 25 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 25 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 27 2018
      Annual report with a comprehensive overview of the company
      Filing Type: 10-KFiling Source: edgar
      Filing Date: March, 27 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 27 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 12 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: ALNA)

      Daily Technical Chart for (NASDAQ: ALNA)


      Stay tuned for daily updates and more on (NASDAQ: ALNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: ALNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ALNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ALNA and does not buy, sell, or trade any shares of ALNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/